文献速递神经CTMR

COVID-19患者的神经影像学表现:系统综述与Meta分析

Neuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis.
PubMed 文献 · Korean J Radiol · 2021-07-01

该系统综述与Meta分析纳入17项研究、1394例接受脑CT或MRI的COVID-19患者,3.4%出现COVID-19相关神经影像学表现,嗅球异常最常见(23.1%),重症患者相关表现比例显著高于其他患者(9.1% vs. 1.6%,p=0.029)。

要点

  • COVID-19患者中COVID-19相关神经影像学表现总体少见,约为3.4%。
  • 嗅球异常是最常见的神经影像学表现,占23.1%。
  • 重症患者出现COVID-19相关神经影像学表现的比例显著高于其他患者(9.1% vs. 1.6%)。

核心结论

  • COVID-19患者中偶可观察到异常神经影像学表现,嗅球异常最常见;重症患者出现异常神经影像学表现的比例高于其他患者组;白质异常、缺血性梗死和脑病是常见的脑部神经影像学表现。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE/PubMed和EMBASE数据库截至2020年9月17日,纳入使用脑CT或MRI评估COVID-19神经影像学表现的研究,共纳入17项研究、1394例接受神经影像学检查的COVID-19患者。

关键影像表现/征象

  • 嗅球异常是最常观察到的表现,占23.1%。
  • 主要的脑部神经影像学表现为白质异常(17.6%),其次为急性/亚急性缺血性梗死(16.0%)和脑病(13.0%)。
  • 3.4%的患者显示COVID-19相关神经影像学表现。
  • 重症患者出现COVID-19相关神经影像学表现的比例显著高于其他患者(9.1% vs. 1.6%;p = 0.029)。
  • 所用影像学检查方式类型对COVID-19相关神经影像学表现的比例无显著影响。

诊断标准与关键数值

  • COVID-19相关神经影像学表现总体发生比例为3.4%。
  • 嗅球异常发生比例为23.1%。
  • 白质异常发生比例为17.6%,急性/亚急性缺血性梗死为16.0%,脑病为13.0%。
  • 重症患者COVID-19相关神经影像学表现比例为9.1%,其他患者为1.6%(p = 0.029)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Central nervous system involvement in coronavirus disease 2019 (COVID-19) has been increasingly reported. We performed a systematic review and meta-analysis to evaluate the incidence of radiologically demonstrated neurologic complications and detailed neuroimaging findings associated with COVID-19.

MATERIALS AND METHODS: A systematic literature search of MEDLINE/PubMed and EMBASE databases was performed up to September 17, 2020, and studies evaluating neuroimaging findings of COVID-19 using brain CT or MRI were included. Several cohort-based outcomes, including the proportion of patients with abnormal neuroimaging findings related to COVID-19 were evaluated. The proportion of patients showing specific neuroimaging findings was also assessed. Subgroup analyses were also conducted focusing on critically ill COVID-19 patients and results from studies that used MRI as the only imaging modality.

RESULTS: A total of 1394 COVID-19 patients who underwent neuroimaging from 17 studies were included; among them, 3.4% of the patients demonstrated COVID-19-related neuroimaging findings. Olfactory bulb abnormalities were the most commonly observed (23.1%). The predominant cerebral neuroimaging finding was white matter abnormality (17.6%), followed by acute/subacute ischemic infarction (16.0%), and encephalopathy (13.0%). Significantly more critically ill patients had COVID-19-related neuroimaging findings than other patients (9.1% vs. 1.6%; p = 0.029). The type of imaging modality used did not significantly affect the proportion of COVID-19-related neuroimaging findings.

CONCLUSION: Abnormal neuroimaging findings were occasionally observed in COVID-19 patients. Olfactory bulb abnormalities were the most commonly observed finding. Critically ill patients showed abnormal neuroimaging findings more frequently than the other patient groups. White matter abnormalities, ischemic infarctions, and encephalopathies were the common cerebral neuroimaging findings.

来源:Korean J Radiol,查看原文。版权归原作者所有。

引用

  1. Kim PH, Kim M, Suh CH, et al. Neuroimaging Findings in Patients with COVID-19: A Systematic Review and Meta-Analysis. Korean J Radiol. 2021. PMID: 34269530. doi:10.3348/kjr.2021.0127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。